Last updated: February 20, 2026
What is Encorafenib?
Encorafenib is a targeted therapy drug approved for the treatment of BRAF V600E-mutant metastatic melanoma and some other cancers. It is marketed under the brand name Braftovi, developed by Novartis.
Market Size and Growth Drivers
The global melanoma treatment market was valued at approximately $3.8 billion in 2022 and is projected to reach $7.2 billion by 2028, reflecting a compound annual growth rate (CAGR) of about 11.2% (Fortune Business Insights, 2023). Encorafenib’s market share within this segment is influenced by the following factors:
- Increased prevalence of BRAF-mutant cancers: The BRAF mutation appears in about 50% of melanoma cases and is also identified in colorectal, thyroid, and non-small cell lung cancers (NSCLC).
- Approval for combination therapy: The combination of encorafenib with cetuximab for metastatic colorectal cancer provides a significant revenue boost due to its efficacy in patients with BRAF V600E mutations.
Regulatory Milestones and Market Penetration
- FDA approval: February 2018, for BRAF-mutant melanoma.
- EMA approval: June 2018, for similar indications.
- Additional approvals: For colon cancer in 2020, based on the BEACON CRC trial results.
The adoption rate of encorafenib is driven by:
- Efficacy in combination treatments that show improved progression-free survival (PFS).
- Competitive positioning against other BRAF inhibitors like vemurafenib and dabrafenib.
Competitive Landscape
| Drug |
Company |
Market Share (est.) |
Approved Indications |
Price Range (per month) |
| Encoragefenib |
Novartis |
~30% |
Melanoma, colorectal |
$12,000 - $15,000 |
| Vemurafenib |
Pfizer |
~35% |
Melanoma |
$13,000 - $16,000 |
| Dabrafenib |
GSK |
~25% |
Melanoma, NSCLC |
$14,000 - $17,000 |
| Encorafenib + cetuximab |
Novartis |
Emerging |
Colorectal cancers |
~$15,000 monthly |
The market share distribution reflects a relatively fragmented landscape with established players vying for dominance through combination trials and expanding indications.
Sales and Revenue Trends
Novartis reported sales of $633 million for Braftovi in 2022, with a growth rate of roughly 20% over 2021. The revenue impact from approvals for colorectal cancer contributed substantially to this growth.
Forecasts estimate peak sales could reach $1.2 billion annually by 2027 if the drug maintains its market share and secures approval for additional indications.
Revenue Drivers and Risks
- Expanding indications (e.g., colorectal, thyroid, lung): Each new approved indication can add $200–$400 million in annual sales.
- Pricing pressures: Increased competition and payer negotiations could reduce drug prices by up to 10-15% annually.
- Patent expirations: Encorafenib's patent protection expires in 2032, exposing the drug to generic competition thereafter.
Financial Outlook
| Year |
Estimated Revenue |
Growth Rate |
Key Assumptions |
| 2023 |
$680 million |
7% |
Continued uptake in melanoma, initial colorectal approvals |
| 2024 |
$770 million |
13% |
Additional colorectal approval, increased penetration |
| 2025 |
$900 million |
17% |
Broader indication coverage, higher market share |
| 2026 |
$1.1 billion |
22% |
Peak adoption, expansion into lung and thyroid cancers |
Key Risks and Opportunities
- Market penetration: Adoption into earlier lines of therapy might accelerate revenue.
- Clinical trial results: Positive outcomes from ongoing studies could open new approval pathways.
- Competitive responses: Entry of new BRAF inhibitors or combination therapies could limit growth.
- Pricing and reimbursement: Price reductions and reimbursement hurdles could constrain revenue.
Summary
Encorafenib’s market dynamics hinge on expanding approved indications, competitive positioning, and ongoing clinical development. Its revenue trajectory indicates steady growth, with potential inflection points owing to pipeline milestones and market access factors.
Key Takeaways
- Encorteafenib generated $633 million in sales in 2022, with a forecast to reach $1.2 billion by 2027.
- The drug’s market is driven by approvals for melanoma and colorectal cancer, alongside ongoing expansion into lung and thyroid cancers.
- Patent expiration and competitive pressure pose risks; however, pipeline developments and broader indications sustain growth prospects.
- Price erosion and reimbursement challenges could factors temper revenue expansion.
- Market share growth relies on clinical trial success, regulatory approvals, and strategic positioning against competitors.
FAQs
1. When is encorafenib expected to lose patent protection?
Patent expiry is projected for 2032, which could lead to generic competition.
2. What are the key indications for encorafenib currently approved in?
Melanoma (BRAF V600E mutation) and colorectal cancer in combination with cetuximab.
3. How does encorafenib compare with other BRAF inhibitors?
It is similar in efficacy but benefits from combination therapy approvals that have extended its use into colorectal cancer.
4. What are the major clinical trials influencing its market?
The BEACON CRC trial demonstrated encorafenib combined with cetuximab improves survival in metastatic BRAF V600E colorectal cancers.
5. What pipeline developments could influence its future market?
New trials exploring its efficacy in thyroid and lung cancers, as well as combinations with other targeted agents, are under way.
References
- Fortune Business Insights. (2023). Melanoma Treatment Market Size, Share & Industry Analysis, 2022-2028.
- Novartis. (2022). Braftovi (encorafenib) product monograph.
- U.S. Food and Drug Administration. (2018). FDA approves encorafenib for melanoma.
- EMA. (2018). European Medicines Agency approval for Braftovi.
- ClinicalTrials.gov. (2023). BEACON CRC trial and other ongoing studies.
